C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

Table 2 Comparison of trough serum infliximab (IFX) levels, partial Mayo Score and C-reactive protein (CRP) levels in subgroups of ulcerative colitis patients 2 weeks after the initiation of IFX infusion

Variable	IFX responders (n = 29)	IFX partial-responders (n = 24)	IFX non-responders (n = 19)	P₁ Value	P₂ Value
Trough IFX (μg/mL)	23.3 [18.9–29.7]	30.9 [17.7–42.7]	25.0 [21.6–31.5]	0.1825	0.4436
Partial Mayo Score (0–9)	1.0 [0–3.0]	5.0 [3.0–6.0]	7.0 [3.0–8.0]	<0.0001	<0.0001
CRP (mg/dL)	0.07 [0.02–0.24]	0.19 [0.08–0.67]	0.43 [0.16–2.13]	0.0135	0.0084
CRP (week 2/week 0) ratio	0.06 [0.02–0.21]	0.39 [0.08–0.97]	1.00 [0.29–1.89]	0.0025	<0.0001

Data are presented as the median [interquartile range] values and compared by Wilcoxon-Mann–Whitney test
P₁, responder vs partial-responder; P₂: responder vs no-responder

ISSN: 1471-230X